Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD.
OBJECTIVE
Aclidinium-formoterol 400/12 µg is a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist in a fixed-dose combination used in the management of patients with COPD. This study aimed to assess the cost-effectiveness of aclidinium-formoterol 400/12 µg against the long-acting muscarinic antagonist aclidinium bromide 400 µg.


METHODS
A five-health-state Markov transition model with monthly cycles was developed using MS Excel to simulate patients with moderate-to-severe COPD and their initial lung-function improvement following treatment with aclidinium-formoterol 400/12 µg or aclidinium 400 µg. Health states were based on severity levels defined by Global Initiative for Chronic Obstructive Lung Disease 2010 criteria. The analysis was a head-to-head comparison without step-up therapy, from the NHS Scotland perspective, over a 5-year time horizon. Clinical data on initial lung-function improvement were provided by a pooled analysis of the ACLIFORM and AUGMENT trials. Management, event costs, and utilities were health state-specific. Costs and effects were discounted at an annual rate of 3.5%. The outcome of the analysis was expressed as cost (UK£) per quality-adjusted life-year (QALY) gained. The analysis included one way and probabilistic sensitivity analyses to investigate the impact of parameter uncertainty on model outputs.


RESULTS
Aclidinium-formoterol 400/12 µg provided marginally higher costs (£41) and more QALYs (0.014), resulting in an incremental cost-effectiveness ratio of £2,976/QALY. Sensitivity analyses indicated that results were robust to key parameter variations, and the main drivers were: mean baseline forced expiratory volume in 1 second (FEV1), risk of exacerbation, FEV1 improvement from aclidinium-formoterol 400/12 µg, and lung-function decline. The probability of aclidinium-formoterol 400/12 µg being cost-effective (using a willingness-to-pay threshold of £20,000/QALY) versus aclidinium 400 µg was 79%.


CONCLUSIONS
In Scotland, aclidinium-formoterol 400/12 µg can be considered a cost-effective treatment option compared to aclidinium 400 µg alone in patients with moderate-to-severe COPD.
Real World Evidence, IMS Health, Zaventem, Belgium.
Mafalda
M
Ramos
Academic Primary Care Division of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland.
John
J
Haughney
Health Economics and Outcomes Research, Real World Evidence, IMS Health, London, UK.
Nathaniel
N
Henry
AstraZeneca, Barcelona, Spain.
Leandro
L
Lindner
Real World Evidence, IMS Health, Zaventem, Belgium.
Mark
M
Lamotte
LABA; LAMA; Markov model; Scotland; cost-effectiveness; lung-function improvement
Eur Respir J. 2013 Sep;42(3):616-25
23349449
Eur Respir J. 2004 Mar;23(3):456-63
15065839
Value Health. 2005 Jan-Feb;8(1):32-46
15841892
Eur Respir J. 1998 Jun;11(6):1354-62
9657579
Int J Chron Obstruct Pulmon Dis. 2013;8:461-71
24143085
Eur Respir J. 2002 Feb;19(2):209-16
11871363
Respir Res. 2015 Aug 02;16:92
26233481
Eur Respir J. 2001 Nov;18(5):770-9
11757626
Qual Life Res. 2000;9(5):521-7
11190007
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
9872837
Thorax. 2003 May;58(5):399-404
12728159
Clinicoecon Outcomes Res. 2014 Apr 05;6:175-85
24741321
Eur J Health Econ. 2007 Jun;8(2):123-35
17370096
Med Decis Making. 1994 Jan-Mar;14(1):52-8
8152357
Pharmacoeconomics. 2005;23(6):619-37
15960557
Chest. 2006 Oct;130(4):1117-28
17035446
Eur Respir J. 2002 Feb;19(2):217-24
11866001
Ups J Med Sci. 1986;91(3):299-310
3811032
N Engl J Med. 2008 Oct 9;359(15):1543-54
18836213
Value Health. 2012 Sep-Oct;15(6):796-803
22999128
Eur Respir J. 1993 Mar;6 Suppl 16:5-40
24576915
Br J Gen Pract. 2011 Feb;61(583):91-2
21276335
Eur J Health Econ. 2014 Jan;15(1):69-82
23392624
Value Health. 2011 Mar-Apr;14(2):354-60
21402304